Vincent A Miller Selected Research

Erlotinib Hydrochloride (CP 358,774)

11/2017	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
1/2017	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
10/2016	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
1/2016	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
9/2014	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
2/2014	Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.
4/2013	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
7/2012	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
6/2012	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
5/2012	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vincent A Miller Research Topics

Disease

179	Neoplasms (Cancer) 10/2021 - 02/2002
69	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2002
45	Lung Neoplasms (Lung Cancer) 12/2020 - 01/2005
34	Adenocarcinoma of Lung 01/2018 - 01/2005
22	Adenocarcinoma 01/2021 - 03/2004
20	Carcinoma (Carcinomatosis) 01/2020 - 07/2002
19	Breast Neoplasms (Breast Cancer) 11/2020 - 02/2002
15	Neoplasm Metastasis (Metastasis) 03/2021 - 11/2002
14	Colorectal Neoplasms (Colorectal Cancer) 12/2019 - 06/2003
10	Melanoma (Melanoma, Malignant) 01/2019 - 07/2012
7	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 02/2011
7	Microsatellite Instability 01/2020 - 11/2016
7	Disease Progression 02/2016 - 05/2005
6	Exanthema (Rash) 01/2022 - 09/2005
6	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 12/2012
5	Diarrhea 01/2022 - 09/2005
5	Triple Negative Breast Neoplasms 02/2019 - 02/2014
5	Fatigue 11/2017 - 05/2005
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 02/2003
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 08/2015
4	Squamous Cell Carcinoma of Head and Neck 10/2019 - 01/2013
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2017
3	Hematologic Neoplasms (Hematological Malignancy) 12/2018 - 01/2016
3	Hypersensitivity (Allergy) 01/2018 - 02/2008
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2017 - 05/2005
3	Inflammatory Breast Neoplasms 11/2015 - 02/2014
3	Colonic Neoplasms (Colon Cancer) 01/2015 - 07/2012
3	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 05/2011 - 11/2004
3	Stomatitis 08/2007 - 06/2003
2	Glioma (Gliomas) 01/2020 - 11/2016
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 12/2015
2	Testicular Neoplasms (Testicular Cancer) 01/2020 - 01/2019

Drug/Important Bio-Agent (IBA)

58	ErbB Receptors (EGF Receptor)IBA 01/2018 - 06/2003
42	Tyrosine Kinase InhibitorsIBA 01/2021 - 02/2003
40	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2017 - 01/2005
39	Gefitinib (Iressa)FDA Link 01/2022 - 06/2003
38	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2008
30	Phosphotransferases (Kinase)IBA 01/2020 - 01/2005
27	Biomarkers (Surrogate Marker)IBA 12/2020 - 03/2011
26	Pharmaceutical PreparationsIBA 01/2020 - 06/2003
18	Formaldehyde (Formol)FDA Link 01/2020 - 05/2013
18	ParaffinIBA 01/2020 - 05/2013
17	CrizotinibIBA 10/2019 - 09/2012
17	Proteins (Proteins, Gene)FDA Link 01/2019 - 02/2002
16	Immune Checkpoint InhibitorsIBA 10/2021 - 03/2016
12	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 11/2003
12	Anaplastic Lymphoma KinaseIBA 01/2018 - 12/2012
10	Circulating Tumor DNAIBA 10/2020 - 01/2017
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2019 - 04/2010
9	Everolimus FDA Link 01/2021 - 08/2007
9	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 01/2016
8	RNA (Ribonucleic Acid)IBA 01/2020 - 12/2013
8	AfatinibIBA 11/2017 - 05/2012
8	Paclitaxel (Taxol)FDA LinkGeneric 06/2012 - 06/2003
7	Estrogen ReceptorsIBA 11/2020 - 12/2013
7	TOR Serine-Threonine KinasesIBA 09/2017 - 10/2010
6	Biological ProductsIBA 11/2018 - 12/2006
6	Docetaxel (Taxotere)FDA Link 07/2007 - 02/2003
5	Trastuzumab (Herceptin)FDA Link 11/2019 - 02/2002
5	LigandsIBA 12/2018 - 07/2012
4	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 01/2012
4	Monoclonal AntibodiesIBA 12/2019 - 02/2002
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2019 - 05/2014
4	MTOR InhibitorsIBA 01/2019 - 01/2013
4	dabrafenibIBA 01/2018 - 01/2015
4	Cetuximab (Erbitux)FDA Link 11/2017 - 04/2011
4	Mitogen-Activated Protein KinasesIBA 11/2016 - 04/2010
4	Carboplatin (JM8)FDA LinkGeneric 06/2012 - 06/2003
3	AlbuminsIBA 03/2021 - 02/2008
3	PlatinumIBA 12/2020 - 07/2010
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 05/2014
3	Codon (Codons)IBA 12/2019 - 09/2008
3	SolventsIBA 12/2019 - 11/2011
3	osimertinibIBA 12/2019 - 01/2017
3	Cytotoxins (Cytolysins)IBA 01/2019 - 09/2003
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 05/2014
3	Calcibiotic Root Canal SealerIBA 01/2018 - 01/2016
3	trametinibIBA 01/2018 - 01/2015
3	Proto-Oncogene Proteins c-metIBA 01/2017 - 01/2016
3	Sorafenib (BAY 43-9006)FDA Link 10/2016 - 01/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2016 - 08/2007
3	alectinibIBA 01/2016 - 12/2014
3	Threonine (L-Threonine)FDA Link 11/2008 - 03/2005
2	palbociclibIBA 11/2020 - 01/2017
2	HM781-36BIBA 03/2020 - 10/2019
2	Tumor Biomarkers (Tumor Markers)IBA 12/2019 - 11/2004
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2019 - 08/2017
2	Heme (Haem)IBA 12/2018 - 01/2018
2	Cell-Free Nucleic AcidsIBA 11/2018 - 01/2018
2	Cyclin-Dependent Kinase Inhibitor p15IBA 10/2018 - 11/2016
2	Cyclin-Dependent Kinase Inhibitor p16IBA 10/2018 - 11/2016
2	ChromatinIBA 01/2018 - 11/2016

Therapy/Procedure

110	Therapeutics 01/2022 - 03/2005
40	Drug Therapy (Chemotherapy) 12/2020 - 02/2002
10	Immunotherapy 01/2021 - 09/2004
7	Ligation 01/2017 - 01/2014
5	Radiotherapy 01/2017 - 07/2002
4	Precision Medicine 03/2021 - 05/2014
3	Aftercare (After-Treatment) 01/2017 - 03/2008
3	Neoadjuvant Therapy 03/2016 - 02/2014